GenaCheck COVID-19 Rapid Self-Test

The GenaCheck COVID-19 Rapid Self-Test is a lateral flow immunoassay for rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigen from anterior nasal swab specimens. It is intended for non-prescription home use by individuals aged 14 and older testing themselves, or adults testing individuals aged 2 and older who show signs and symptoms of COVID-19 within the first 5 days of symptom onset.

The device uses latex particle-based immunochromatography with anti-SARS-CoV-2 antibodies labeled with latex beads. Results are visually read between 10-30 minutes with two line regions (test and control). Compared to the predicate Flowflex Plus, GenaCheck has a slightly shorter window (5 days vs. 6 days symptom onset) and faster result time (10-30 min vs. 15-30 min), but uses identical lateral flow immunoassay principle, anterior nasal swab specimens, and visual result interpretation.

Not stated in this summary. The document references FDA-cleared RT-PCR comparator assays (cobas SARS-CoV-2) and WHO International Standard for SARS-CoV-2 Antigen (NIBSC 21/368) but does not cite ISO, IEC, or ASTM consensus standards.

Substantial equivalence is established through analytical and clinical performance parity: both devices target the same analyte (SARS-CoV-2 nucleocapsid antigen), use identical lateral flow immunoassay methodology, are designed for anterior nasal self-testing in symptomatic individuals, and achieve comparable accuracy (GenaCheck PPA 93.3%, NPA 98.7% versus predicate's established performance). The minor difference in symptom onset window (5 vs. 6 days) and result timing (10-30 vs. 15-30 min) do not affect the fundamental intended use or performance profile. Comprehensive analytical studies (limit of detection, precision across lots, cross-reactivity, interfering substances) and a 643-subject clinical study demonstrate the device performs safely and effectively equivalent to the predicate for home-use COVID-19 detection.